The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by ...

Further, the study showed that nirsevimab’s effect was less pronounced in older children (between six and 23 months), ...

In response to the global burden of severe RSV disease among infants, WHO recommends that all countries introduce either the ...

As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

RSV is responsible for around 1 lakh deaths, over 3.6 million hospitalisations in children under age of 5 every year, ...

Discover a study that highlights the importance of identifying high-risk children through biomarkers and better understanding ...

RSV leads to over 100,000 infant deaths annually, but WHO’s latest guidance recommends maternal vaccines and monoclonal ...